APA (7th ed.) Citation

Berns, K., Caumanns, J. J., Hijmans, E. M., Gennissen, A. M. C., Severson, T. M., Evers, B., . . . Bernards, R. (2018). ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors. Oncogene, 37(33), 4611-4625. https://doi.org/10.1038/s41388-018-0300-6

Chicago Style (17th ed.) Citation

Berns, Katrien, et al. "ARID1A Mutation Sensitizes Most Ovarian Clear Cell Carcinomas to BET Inhibitors." Oncogene 37, no. 33 (2018): 4611-4625. https://doi.org/10.1038/s41388-018-0300-6.

MLA (9th ed.) Citation

Berns, Katrien, et al. "ARID1A Mutation Sensitizes Most Ovarian Clear Cell Carcinomas to BET Inhibitors." Oncogene, vol. 37, no. 33, 2018, pp. 4611-4625, https://doi.org/10.1038/s41388-018-0300-6.